255 related articles for article (PubMed ID: 28680834)
1. Direct Acting Anti-hepatitis C Virus Drugs: Clinical Pharmacology and Future Direction.
Geddawy A; Ibrahim YF; Elbahie NM; Ibrahim MA
J Transl Int Med; 2017 Mar; 5(1):8-17. PubMed ID: 28680834
[TBL] [Abstract][Full Text] [Related]
2. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
McConachie SM; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
[TBL] [Abstract][Full Text] [Related]
3. Geno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral Agents.
Kalaghatgi P; Sikorski AM; Knops E; Rupp D; Sierra S; Heger E; Neumann-Fraune M; Beggel B; Walker A; Timm J; Walter H; Obermeier M; Kaiser R; Bartenschlager R; Lengauer T
PLoS One; 2016; 11(5):e0155869. PubMed ID: 27196673
[TBL] [Abstract][Full Text] [Related]
4. Grazoprevir/elbasvir combination therapy for HCV infection.
Vallet-Pichard A; Pol S
Therap Adv Gastroenterol; 2017 Jan; 10(1):155-167. PubMed ID: 28286567
[TBL] [Abstract][Full Text] [Related]
5. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
6. Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients.
Hull MW; Yoshida EM; Montaner JS
Curr Infect Dis Rep; 2016 Jul; 18(7):22. PubMed ID: 27357277
[TBL] [Abstract][Full Text] [Related]
7. Direct anti-HCV agents.
Zhang X
Acta Pharm Sin B; 2016 Jan; 6(1):26-31. PubMed ID: 26904396
[TBL] [Abstract][Full Text] [Related]
8. Molecular Mechanisms of Resistance to Direct-Acting Antiviral (DAA) Drugs for the Treatment of Hepatitis C Virus Infections.
Izhari MA
Diagnostics (Basel); 2023 Sep; 13(19):. PubMed ID: 37835845
[TBL] [Abstract][Full Text] [Related]
9. A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Tao W; Gan T; Lu J; Zhong J
Antiviral Res; 2017 Mar; 139():18-24. PubMed ID: 28025084
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection.
Martinello M; Dore GJ; Skurowski J; Bopage RI; Finlayson R; Baker D; Bloch M; Matthews GV
Open Forum Infect Dis; 2016 Apr; 3(2):ofw105. PubMed ID: 27419177
[TBL] [Abstract][Full Text] [Related]
11. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
12. Treatment of hepatitis C: Results in real life.
Hézode C
Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
[TBL] [Abstract][Full Text] [Related]
13. Current race in the development of DAAs (direct-acting antivirals) against HCV.
De Clercq E
Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Yu ML
J Gastroenterol Hepatol; 2017 Aug; 32(8):1436-1442. PubMed ID: 28124463
[TBL] [Abstract][Full Text] [Related]
15. Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis.
Majumdar A; Kitson MT; Roberts SK
Aliment Pharmacol Ther; 2016 Jun; 43(12):1276-92. PubMed ID: 27087015
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.
De Monte A; Courjon J; Anty R; Cua E; Naqvi A; Mondain V; Cottalorda J; Ollier L; Giordanengo V
J Clin Virol; 2016 May; 78():27-30. PubMed ID: 26967675
[TBL] [Abstract][Full Text] [Related]
17. Drug-drug interactions during antiviral therapy for chronic hepatitis C.
Kiser JJ; Burton JR; Everson GT
Nat Rev Gastroenterol Hepatol; 2013 Oct; 10(10):596-606. PubMed ID: 23817323
[TBL] [Abstract][Full Text] [Related]
18. Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.
Ramirez S; Mikkelsen LS; Gottwein JM; Bukh J
Gastroenterology; 2016 Nov; 151(5):973-985.e2. PubMed ID: 27453546
[TBL] [Abstract][Full Text] [Related]
19. Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?
Fabrizi F; Messa P
Expert Rev Clin Pharmacol; 2015; 8(6):785-93. PubMed ID: 26365524
[TBL] [Abstract][Full Text] [Related]
20. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
